Inflammation, Atherosclerosis, and Coronary Artery Disease | NEJM Skip to main content NEJM
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …

Atherosclerosis, the cause of myocardial infarction, stroke, and ischemic gangrene, is an
inflammatory disease. The atherosclerotic process is initiated when cholesterol-containing …

Background Preliminary reports of studies involving simple coronary lesions indicate that a
sirolimus-eluting stent significantly reduces the risk of restenosis after percutaneous …

Background The need for repeated treatment of restenosis of a treated vessel remains the
main limitation of percutaneous coronary revascularization. Because sirolimus (rapamycin) …

Objective The phenotypic plasticity of vascular smooth muscle cells (VSMCs) is central to
vessel growth and remodeling, but also contributes to cardiovascular pathologies. New …

Coronary artery stents revolutionized the practice of interventional cardiology after they were
first introduced in the mid-1980s. Since then, there have been significant developments in …

Cell growth (an increase in cell mass and size through macromolecular biosynthesis) and
cell cycle progression are generally tightly coupled, allowing cells to proliferate continuously …

Sirolimus is the USAN-assigned generic name for the natural product rapamycin. Sirolimus
is produced by a strain of Streptomyces hygroscopicus, isolated from a soil sample collected …

The Japanese Circulation Society (JCS) published the “Guidelines for elective percutaneous
coronary intervention [PCI] in patients with stable coronary disease” in 2000. In 2006 …

Background Although thrombosis is considered the cardinal feature of the antiphospholipid
syndrome, chronic vascular lesions are common, particularly in patients with life-threatening …